Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 1999

View Archived Issues

MUC1 mucin expression related to T-cell activation

Reticulose enhances efficacy of HAART cocktail in two case studies

Amrad to distribute PathoGenesis's inhalable CF treatment in Australia

Bayer to acquire OSI's diagnostics business

Patent licensed to Endorex/Elan joint venture covers mucosal delivery systems

Preliminary phase III results disappointing for Anogesic as anal fissure therapy

Gliatech soon to begin phase II Perceptin trials in ADHD

Abbott acquires anesthesia/analgesia products from Glaxo Wellcome

Abbott and Alza update merger proceedings

Pozen licenses migraine prophylactic from Roche

AxyS and Merck extend osteoporosis collaboration

Once-weekly Fosamax as effective as daily dosing

Xenova's IND for multidrug resistance modulator gets FDA approval

Novel antitumor agents for both leukemias and solid tumors discovered by Taiwanese scientists

Calcimimetics and calcilytics designed at NPS

Sanofi-Synthelabo pipeline includes compounds with neurotrophic/neuroprotective effects

Calcium channel blockers with piperidine structure synthesized at NeuroSearch

Abbott's new LHRH antagonists, pharmaceutical compositions and use

Korean investigators disclose new hepatoprotective agents

Methylenecyclopropane nucleoside analogues as effective agents for CMV infections

Eradication of H. pylori infection obtained with low doses of new cephem

Azimilide pharmacokinetics not significantly affected by severe renal impairment

Pharmacokinetics and pharmacodynamics of eniporide assessed over wide dose range

WHI-D12 is a potent and selective inhibitor of Bruton's tyrosine kinase

New acylfulvene analogues with clinical potential identified by MGI Pharma

Geldanamycin derivative with selective activity against breast cancer developed at Sloan-Kettering

Gender does not affect PK of Sch-58235: results presented at 1999 AAPS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...